Phase I Study of Sapanisertib in Combination with Ziv-Aflibercept (NSC# 724770) in Patients with Advanced Cancers Including Pancreatic Cancer
Summary
The purpose of this phase I trial is to study the side effects and best dose of Sapanisertib and ziv-aflibercept in treating patients with solid tumors that have come back and have spread to another place in the body or cannot be removed by surgery. Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
General Information
NCT#: NCT02159989
Study ID: 2013-0665 NCI-2014-01107
Trial Phase: Phase I
Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Ziv-Aflibercept, Sapanisertib